Fujimoto Yutaka, Shiraishi Sachika, Yamanaka Masashi, Yamano Akihiro, Matsumoto Kazuki, Shiba Shintaro, Tsukiyama Toshitaka, Kobayashi Masahiro, Tokuuye Koichi
Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan.
Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan;
In Vivo. 2025 May-Jun;39(3):1654-1660. doi: 10.21873/invivo.13966.
BACKGROUND/AIM: Spot scanning proton beam therapy (SS-PBT) was employed for the treatment of surgery-inaccessible hepatocellular carcinoma, primarily influenced by respiratory movement.
Between October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.
The one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.
SS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.
背景/目的：采用点扫描质子束疗法（SS-PBT）治疗难以进行手术的肝细胞癌，此类癌症主要受呼吸运动影响。
2022年10月至2023年12月期间，12例患者纳入本研究以评估SS-PBT的疗效。中位随访时间为13.1个月。
1年生存率、无进展生存率和局部控制率分别为79.5%、57.1%和100%，无2级或更高的与质子束疗法相关的毒性反应。这12例患者的临床结果似乎与日本各质子中心开展的前瞻性研究数据相当。
SS-PBT有望成为难以进行手术的肝细胞癌的一种治疗选择。
